Friday, January 6, 2017

Sanofi Counts Cost of Praluent Ruling

A ruling by a U.S. judge to permanently block the sale of Sanofi’s new cholesterol-lowering drug could deal a blow to the French drugmaker’s ambitions for what it hoped would become a blockbuster product.

from WSJ.com: US Business http://ift.tt/2hXycy5
via IFTTT

No comments:

Post a Comment